Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by New World Advisors LLC

New World Advisors LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,813 shares of the medical equipment provider’s stock after purchasing an additional 260 shares during the quarter. New World Advisors LLC’s holdings in Zimmer Biomet were worth $403,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of ZBH. Equity Investment Corp acquired a new stake in Zimmer Biomet during the 3rd quarter valued at approximately $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its holdings in Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after buying an additional 577,320 shares during the last quarter. Van ECK Associates Corp lifted its holdings in Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after buying an additional 411,163 shares during the last quarter. Thompson Siegel & Walmsley LLC bought a new position in Zimmer Biomet during the 3rd quarter worth approximately $41,588,000. Finally, FMR LLC lifted its holdings in Zimmer Biomet by 27.6% during the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after buying an additional 162,384 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.2 %

Shares of ZBH stock opened at $104.89 on Monday. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The stock has a market cap of $20.88 billion, a PE ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The business’s fifty day moving average is $105.86 and its 200-day moving average is $107.46. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business posted $2.20 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is 21.57%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Stifel Nicolaus increased their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James reduced their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.